New Delhi: Consider the burden of health care and the cost of buying three doses, Zydus Cadila plans to find approval for a two-dose regimen from the Covid-19 vaccine-free needle, Zycov-D, the day after the vaccine was approved by the Indian drug regulator for emergency use in India at 20 August.
Trial for a two-dose regimen is ongoing.
2mg vaccines have been prescribed in every dose of three-dose vaccines today.
A total of 6 mg.
The company now evaluates the regime of 2 doses with 3mg in each dose.
This vaccine is said to be worshiped because this for the first time the advanced vaccine that technology has been successfully developed on the Plasmid DNA platform for human use.
Plasmid DNA vaccines use DNA molecules that are not replication.
According to Zydus Cadila, a vaccine which when managed produces a protein surge in the SARS-COV-2 virus and raises the immune response mediated by the cellular and humoral arm of the human immune system, which plays an important role of disease as well as viral permits.
The platform because fast plug-and-play technology can be easily adapted to handle mutations on viruses, as they have occurred.
The company plans to produce 10-12 doses of Zycov-D crore every year.
Vaccines are stored at 2-8 degrees Celsius.
Unlike the Pfizer and Moderna vaccines that need to be stored at very cold temperatures, Zycov-D can be stored at 2 to 8 degrees.
This vaccine is also effective against the Delta variant of Covid-19.
Zycov-D is a needle-free and managed intradermally done using pharmajet, a needle-free applicator that ensures painless vaccination.
This will help in providing vaccines to children.
This vaccine is likely to be available in early October, the source said to Ani on Saturday.
Recently in an exclusive interview with Ani, Dr.
Sharvil Patel, managing director Zydus Group said that the vaccine supply would begin from October and so on.
“The vaccine supply will begin in mid-September and from October and so on, supply will be increased to one dose of crore per month,” said Patel.
At the supply of the expected vaccine until December, Patel said the company expects to increase 1 dose of crore per month from October and it will supply 4-5 doses of crore per month to January 2022.
“We can increase vaccine production to 1 crore a month from October at the factory New production, and is expected to supply 4-5 million doses until January 2022, “he said.
According to the Ministry of Health and Family Welfare (Mohfw), with administration of 72.86,883 vaccine doses in the last 24 hours, the coverage of the country’s Covid-19 vaccination exceeded the cumulative number 73.82CR (73.82.07.378) as per temporary report until 7am on Sunday.
This has been achieved through 75.25,766 sessions, stating the ministry.
At present, Covishield, Covaxin, and Sputnik V vaccine are given to a qualified population above 18 years.